Regulatory Archives - Page 9 of 49

Inside Information: Faron to advance bexmarilimab into a registrational Phase 2/3 study in treatment-naïve (frontline) HR-MDS after positive meeting with the FDA

18.8.2025

Faron Pharmaceuticals Ltd | Company announcement | August 18, 2025 at 09:00:00 EEST

Inside Information: Accelerated approval pathway confirmed for frontline patients with CR + CReq, and Overall Survival as primary endpoints

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies, today announces it has received positive and valuable feedback from the U.S. Food and Drug Administration (FDA) regarding the proposed clinical development plan leading to approval for bexmarilimab, its wholly-owned, novel precision cancer immunotherapy.

The feedback was received as part of the Company’s recent BEXMAB study’s end-of-phase 2 (EOP2) meeting with the FDA. The FDA advised Faron to focus on frontline development since possible frontline approval enables use across the entire HR MDS indication. The meeting was requested to gain alignment on the design of a planned registrational phase 2/3 trial evaluating bexmarilimab in combination with azacitidine for patients with treatment-naïve (frontline) higher-risk myelodysplastic syndrome (HR-MDS). Key objectives included obtaining the FDA’s input on the proposed trial design, dosing strategy and clinical endpoints intended to support regulatory approval.

Following the FDA’s guidance, the trial will begin with a dose optimisation run-in period comparing 1 mg/kg and 3 mg/kg regimens with placebo, all in combination with azacitidine. Once the optimal dose has been determined, the trial will seamlessly transition into the registrational stage, which includes an interim analysis to support accelerated approval based on IWG 2023 response criteria in frontline patients.

“We are extremely encouraged by the collaborative and highly productive dialogue with the FDA, which provided a clear and actionable path for the clinical development of bexmarilimab in frontline HR-MDS, an area of profound unmet medical need,” said Dr. Juho Jalkanen, Chief Executive Officer of Faron. “The agency’s guidance has endorsed a direct route towards accelerated approval using Complete Response (CR) + CR equivalent (CReq) per International Working Group (IWG) 2023 criteria as a co-primary endpoint with Overall Survival (OS). This is a significant step forward in our mission to provide a potentially transformative new treatment option to patients and represents a major regulatory de-risking milestone, as we are now only one study away from getting bexmarilimab approved for the benefit of HR MDS patients.”

The FDA confirmed IWG 2023-defined CR + CReq as an acceptable primary endpoint to support an application for accelerated approval in frontline patients. In line with this guidance, Faron will include CR + CReq as a co-primary efficacy endpoint along with Overall Survival (OS) in the phase 2/3 trial. The Company will seek accelerated approval based on an interim readout on the CR + CReq data in frontline patients. Composite complete remission (cCR) will be evaluated as the key secondary endpoint. In addition to the clinical discussion, the FDA was satisfied with Faron’s approach to non-clinical and CMC activities for phase 2/3 and subsequent steps to approval.

“Improving outcomes of patients with HR-MDS continues to be a top priority for our field. Bexmarilimab is an antibody with a novel mechanism of action that has demonstrated promising safety and activity in combination with azacitidine in phase 1/2 clinical trials in the first- and second-line settings for HR-MDS,” added Dr. Amer Zeidan, MBBS, MHS, Professor of Medicine at Yale School of Medicine and Chief of the Division of Hematologic Malignancies at Yale Cancer Center and Smilow Cancer Hospital. “I am thrilled that we have agreed with the regulators on a pathway to explore the full potential of bexmarilimab in the frontline setting for patients with HR-MDS. I also would like to highlight the FDA accepting the use of CR+CReq IWG 2023 criteria as part of the primary endpoint, making this the first registrational clinical trial to do so. Many experts, including myself, strongly believe the IWG 2023 criteria to be more patient centric and reflect clinically meaningful benefits to patients in a more robust fashion than the old IWG 2006 criteria, which have been used for all past (and failed) phase 3 clinical trials for HR-MDS,” concluded Dr. Zeidan.

Disclosure: Dr Amer Zeidan has consulted and received honoraria from Faron. The views expressed as his personal views and not necessarily those of his employer.

For more information, please contact:

IR Partners, Finland (Media) Kare Laukkanen	+358 50 553 9535 / +44 7 469 766 223 kare.laukkanen@irpartners.fi
FINN Partners, US (Media) Alyssa Paldo	+1 847 791-8085 alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP (Nominated Adviser and Broker) Sandy Jamieson, Jo Turner	+44 (0) 207 213 0880
Sisu Partners Oy (Certified Adviser on Nasdaq First North) Juha Karttunen Jukka Järvelä	+358 (0)40 555 4727 +358 (0)50 553 8990

About BEXMAB
The BEXMAB study is an open-label Phase I/II clinical trial investigating bexmarilimab in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective is to determine the safety and tolerability of bexmarilimab in combination with SoC (azacitidine) treatment. Directly targeting Clever-1 could limit the replication capacity of cancer cells, increase antigen presentation, ignite an immune response, and allow current treatments to be more effective. Clever-1 is highly expressed in both AML and MDS and associated with therapy resistance, limited T cell activation and poor outcomes.

About bexmarilimab
Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.

About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.

Forward-Looking Statements
Certain statements in this announcement are, or may be deemed to be, forward-looking statements. Forward looking statements are identified by their use of terms and phrases such as ”believe”, ”could”, “should”, “expect”, “hope”, “seek”, ”envisage”, ”estimate”, ”intend”, ”may”, ”plan”, ”potentially”, ”will” or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors’ current expectations and assumptions regarding the Company’s future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward-looking statements reflect the Directors’ current beliefs and assumptions and are based on information currently available to the Directors.

A number of factors could cause actual results to differ materially from the results and expectations discussed in the forward-looking statements, many of which are beyond the control of the Company. In addition, other factors which could cause actual results to differ materially include the ability of the Company to successfully license its programs within the anticipated timeframe or at all, risks associated with vulnerability to general economic and business conditions, competition, environmental and other regulatory changes, actions by governmental authorities, the availability of capital markets or other sources of funding, reliance on key personnel, uninsured and underinsured losses and other factors. Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward-looking statements. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements.

Faron Pharmaceuticals Ltd: Holding(s) in Company

8.8.2025

Faron Pharmaceuticals Ltd | Company announcement | August 08, 2025 at 17:00:00 EEST

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ⁱⁱ:			Faron Pharmaceuticals Ltd
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer						X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights						X
Other (please specify) ⁱⁱⁱ: Change due theAdvanced Amortisation of the First Tranche Bonds						X
3. Details of person subject to the notification obligation ^iv
Name			Timo Syrjälä
City and country of registered office (if applicable)			Monaco
4. Full name of shareholder(s) (if different from 3.) ^v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reached ^vi:			07/08/2025
6. Date on which issuer notified (DD/MM/YYYY):			08/02/2025
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer (8.A + 8.B) ^vii
Resulting situation on the date on which threshold was crossed or reached	14.997%			14.997%	16,918,396
Position of previous notification (if applicable)	15.15%			15.15%	16,903,396

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached ^viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights ^ix					% of voting rights
		Direct (DTR5.1)		Indirect (DTR5.2.1)			Direct (DTR5.1)		Indirect (DTR5.2.1)
FI4000153309		5,330,368		11,588,028			4.73%		10.27%


SUBTOTAL 8. A		16,918,396					14.997 %

B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument		Expiration date ^x	Exercise/ Conversion Period ^xi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights



			SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument	Expiration date ^x		Exercise/ Conversion Period ^xi		Physical or cash Settlement ^xii			Number of voting rights	% of voting rights



					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer ^xiii
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) ^xiv				X
Name ^xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Timo Syrjälä (Direct)	4.73%		4.73%
Acme Investments SPF Sarl (Indirect)	10.27%		10.27%




10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held

11. Additional information ^xvi
Faron Advanced Amortisation of the First Tranche Bonds 07.08.2025

Place of completion	Monaco
Date of completion	08/08/2025

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds

7.8.2025

Faron Pharmaceuticals Ltd | Company announcement | August 07, 2025 at 09:00:00 EEST

Turku, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the Company has approved the exercise of 857,322 special rights entitling to 857,322 existing treasury shares, for an aggregate subscription price of EUR 1,682,067, in connection with an advanced amortisation payment of the First Tranche Bonds (as defined below), which will occur latest on 8 August 2025. In addition, the Company has made the second scheduled amortisation payment of the First Tranche Bonds in cash on 2 August 2025.

The Company announced on 3 April 2025 that it had entered into a convertible bond arrangement for up to EUR 35 million with an entity managed by Heights Capital Management, Inc. (“HCM”) and resolved upon the issuance of amortising senior unsecured convertible bonds with an aggregated principal amount of EUR 15 million (the “First Tranche Bonds”) due 2 April 2028 to HCM, convertible into new and/or existing shares in the Company (the “Shares”). HCM (or any future holders of the majority of the First Tranche Bonds) may, at any time between scheduled amortisations, exercise their right to bring forward up to two (2) additional amortisation payments (an “Accelerated Amortisation”) to be paid in advance, with a limit of no more than nine (9) Accelerated Amortisations in the first year of the term of the First Tranche Bonds. As previously announced, the Board of Directors of Faron has resolved to make amortisations and interest payments by converting the relevant amounts due into Shares (“Share Settlement Option”), unless it separately decides to make payments in cash. The exercise of the Company’s Share Settlement Option is effected by the bondholders exercising special rights entitling into Shares, as referred to in Chapter 10 of the Finnish Companies Act (“Special Rights”), issued in connection with the issuance of the First Tranche Bonds.

The Company has on 6 August 2025 received an amortised payment advancement notice from the bondholder for an aggregate amortised payment amount (including accrued interest) of EUR 1,682,067. As the Company has exercised its Share Settlement Option, the subscription price for the Shares subscribed for by the bondholder is EUR 1.962 per Share, corresponding to 90 per cent of the lowest of (i) the volume weighted average price (“VWAP”) of a Share on the relevant payment date, and (ii) the lowest of the VWAPs of a Share on each of the five consecutive dealing days ending on (and including) the dealing day immediately preceding the relevant payment date]. Therefore, the Company has approved the exercise of 857,322 Special Rights entitling to 857,322 existing treasury Shares, for an aggregate subscription of EUR 1,682,067. The subscription price for the Shares subscribed for pursuant to the Special Rights is paid by setting off the Company’s debt to pay relevant amounts due under the First Tranche Bonds and recorded into the reserve for invested unrestricted equity. The new Maturity Date of the Bond is 2 December 2027.

The 857,322 Shares subscribed for rank pari passu in all respects with the existing shares of the Company and are admitted to trading on Nasdaq First North Growth Market Finland (“First North“) maintained by Nasdaq Helsinki Ltd (“Nasdaq Helsinki“) and on AIM (“AIM“), the market of that name operated by London Stock Exchange plc (the “LSE“).

Following the issuance, the aggregate number of ordinary shares in issue in the Company remains 116,954,597. Shares held in treasury by the Company do not confer a right to dividends or other shareholder rights. Following the issuance, the Company will have 4,142,678 shares in treasury and therefore, the total number of voting rights in Faron will be 112,811,919 (the “Number of Shares and Votes“). This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the Number of Shares and Votes of the Company.

For more information, please contact:

IR Partners, Finland (Media) Riina Tuominen Kare Laukkanen	+358 44 313 5005 riina.tuominen@irpartners.fi +358 50 553 9535 / +44 7 469 766 223 kare.laukkanen@irpartners.fi
FINN Partners, US (Media) Alyssa Paldo	+1 847 791-8085 alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP (Nominated Adviser and Broker) Sandy Jamieson, Jo Turner	+44 (0) 207 213 0880
Sisu Partners Oy (Certified Adviser on Nasdaq First North) Juha Karttunen Jukka Järvelä	+358 (0)40 555 4727 +358 (0)50 553 8990

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.

Inside Information: Faron to present updated BEXMAB data in frontline HR-MDS to FDA; complete remission rate substantially increased to 43%

6.8.2025

Faron Pharmaceuticals Ltd | Company announcement | August 06, 2025 at 09:00:00 EEST

Inside Information: Complete remission rate in frontline HR-MDS patients rose from 28% to 43% in latest data cut, confirming the deepening of responses over time.

TURKU, FINLAND– Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunological pathways, today announced an increase in the complete remission (CR) rate in patients with frontline or treatment-naïve high-risk myelodysplastic syndrome (HR-MDS), based on updated efficacy data from its Phase 1/2 BEXMAB trial.

According to the investigator-assessed response using IWG 2006 criteria, as per protocol, the CR rate (as explained below) has increased to 43% (9 out of 21 patients), a substantial improvement from the 28% rate, seen in the earlier data cut. This data builds on the phase II results featured in recent oral presentation at the 2025 American Society of Clinical Oncology (ASCO) congress. This improvement in CR is a result of patient responses improving as they continue longer on the combination therapy of bexmarilimab and the standard-of-care, azacitidine. This updated efficacy data was prepared for an upcoming End-of-Phase 2 (EOP2) meeting with the US Food and Drug Administration (FDA).

CR signifies a return to normal blood cell counts and bone marrow cellularity. This rate was measured using the internationally recognized and stringent, protocol pre-specified criteria. The 43% CR rate achieved with the bexmarilimab combination is more than double the 16-17% historical rate seen in patients treated with azacitidine alone, representing a major therapeutic advance. Earlier data from the BEXMAB study had also reported an encouraging 50% composite CR rate (cCR) in frontline HR-MDS patients, and in essence more and more of these cCR responses are turning into CR over time.

“The continued maturation of the BEXMAB data demonstrates bexmarilimab’s profound impact as a disease-modifying agent,” said Dr. Petri Bono, Chief Medical Officer of Faron. “Seeing the CR rate strengthen over time to 43%, which complements the robust 50% cCR we have already reported, is very encouraging. It provides us with two compelling and clinically meaningful data sets for discussion with the FDA and gives us confidence in proposing a randomized registrational trial designed for accelerated approval with either CR or cCR as the primary endpoint.”

For more information, please contact:

IR Partners, Finland (media)
Riina Tuominen
+358 44 313 5005
riina.tuominen@irpartners.fi

Kare Laukkanen
+358 50 553 9535 / +44 7 469 766 223
kare.laukkanen@irpartners.fi

FINN Partners, US (media)
Alyssa Paldo
+1 847 791-8085
alyssa.paldo@finnpartners.com

Cairn Financial Advisers LLP, Nominated Adviser and Broker
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213 0880

Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990

About BEXMAB

The BEXMAB study is an open-label Phase I/II clinical trial investigating bexmarilimab in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective is to determine the safety and tolerability of bexmarilimab in combination with SoC (azacitidine) treatment. Directly targeting Clever-1 could limit the replication capacity of cancer cells, increase antigen presentation, ignite an immune response, and allow current treatments to be more effective. Clever-1 is highly expressed in both AML and MDS and associated with therapy resistance, limited T cell activation and poor outcomes.

About bexmarilimab

Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.

About Faron Pharmaceuticals Ltd.

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.

Forward-Looking Statements

Certain statements in this announcement are, or may be deemed to be, forward-looking statements. Forward looking statements are identified by their use of terms and phrases such as ”believe”, ”could”, “should”, “expect”, “hope”, “seek”, ”envisage”, ”estimate”, ”intend”, ”may”, ”plan”, ”potentially”, ”will” or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors’ current expectations and assumptions regarding the Company’s future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward-looking statements reflect the Directors’ current beliefs and assumptions and are based on information currently available to the Directors.

Faron Pharmaceuticals Ltd: Director Dealing

2.7.2025

Faron Pharmaceuticals Ltd | Company announcement | July 02, 2025 at 13:00:00 EEST

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Mr. Tuomo Pätsi, Non-Executive Chairman of the Company, acquired 21,500 ordinary shares in Faron at price of €2.435 per share on 30 June 2025. Following this purchase, Mr. Pätsi directly holds 53,265 ordinary shares in the Company, representing 0.05 per cent. of the voting rights in the Company.

Further details are set out in the Notification of Dealing Form below.

Director	Holding prior to purchase	Number of ordinary shares	Resultant interest in ordinary shares in the Company	Resultant percentage of voting rights in the Company
Tuomo Pätsi	31,765	21,500	53,265	0.05%

For more information, please contact:

IR Partners, Finland (Media) Riina Tuominen Kare Laukkanen	+358 44 313 5005 riina.tuominen@irpartners.fi +358 50 553 9535 / +44 7 469 766 223 kare.laukkanen@irpartners.fi
FINN Partners, US (Media) Alyssa Paldo	+1 847 791-8085 alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP (Nominated Adviser and Broker) Sandy Jamieson, Jo Turner	+44 (0) 207 213 0880
Sisu Partners Oy (Certified Adviser on Nasdaq First North) Juha Karttunen Jukka Järvelä	+358 (0)40 555 4727 +358 (0)50 553 8990

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Tuomo Pätsi
2	Reason for notification
a.	Position/Status	Non-Executive Chairman
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Faron Pharmaceuticals Ltd.
b.	LEI	7437009H31TO1DC0EB42
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary Shares ISIN: FI4000153309
b.	Nature of the transaction	Purchase of ordinary shares
			Price(s) per share (p)	Volume(s)
			€2.435	21,500

d.	Aggregated information Volume Price	Volume 21,500 Unit price: 2.435 EUR
e.	Date of the transaction	30/06/2025
f.	Place of the transaction	Nasdaq First North Growth Market

Faron Pharmaceuticals Ltd: Director/PCA Dealing

30.6.2025

Faron Pharmaceuticals Ltd | Company announcement | June 30, 2025 at 14:00:00 EEST

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Dr Juho Jalkanen, Chief Executive Officer of the Company, acquired 22,127 ordinary shares in Faron at price of €2.26 per share on 27 June 2025. Following this purchase, Dr Jalkanen directly holds 1,112,015 ordinary shares in the Company, representing 0.99 per cent of the voting rights in the Company.

Additionally, Dr Juho Jalkanen acquired 2,000 ordinary shares in Faron at a price of 2.27 EUR per share on 27 June 2025 on behalf of his daughter.

Further details are set out in the Notification of Dealing Form below.

Director/PCA	Holding prior to purchase	Number of ordinary shares	Resultant interest in ordinary shares in the Company	Resultant percentage of voting rights in the Company
Juho Jalkanen	1,089,888	22,127	1,112,015	0.99%
Evelina Jalkanen*	Nil	2,000	2,000	0,00%

*Individuals deemed as a PCA to Juho Jalkanen

For more information, please contact:

IR Partners, Finland (Media) Riina Tuominen Kare Laukkanen	+358 44 313 5005 riina.tuominen@irpartners.fi +358 50 553 9535 / +44 7 469 766 223 kare.laukkanen@irpartners.fi
FINN Partners, US (Media) Alyssa Paldo	+1 847 791-8085 alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP (Nominated Adviser and Broker) Sandy Jamieson, Jo Turner	+44 (0) 207 213 0880
Sisu Partners Oy (Certified Adviser on Nasdaq First North) Juha Karttunen Jukka Järvelä	+358 (0)40 555 4727 +358 (0)50 553 8990

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	a) Juho Jalkanen b) Eveliina Jalkanen
2	Reason for notification
a.	Position/Status	a) Chief Executive Officer b) PCA
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Faron Pharmaceuticals Ltd.
b.	LEI	7437009H31TO1DC0EB42
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary Shares ISIN: FI4000153309
b.	Nature of the transaction	Purchase of ordinary shares
			Price(s) per share (p)	Volume(s)
			a) €2.26 b) €2.27	a) 22,127 b) 2,000

d.	Aggregated information Volume Price	Transaction details (a) (1): Volume 22,217 Unit price: 2.26 EUR Transaction details (b) (1): Volume 2,000 Unit price: 2.27 EUR
e.	Date of the transaction	27/06/2025
f.	Place of the transaction	Nasdaq First North Growth Market

Faron Pharmaceuticals Ltd: Director/PCA Dealing and Donation of Shares to Foundation

5.6.2025

Faron Pharmaceuticals Ltd | Company announcement | June 05, 2025 at 18:00:00 EEST

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces that its founding members Markku Jalkanen, a director of the Company, and his spouse Sirpa Jalkanen have on 3 June 2025 donated 500,000 ordinary shares in the Company to the Finnish Foundation that bears their name (“Sirpa ja Markku Jalkasen Säätiö sr”, Business ID 1729345-2) (the ”Foundation”). Markku Jalkanen donated 400,000 ordinary shares and Sirpa Jalkanen donated 100,000 ordinary shares.

The purpose of the Foundation is to promote and support high-quality medical research in Finland, and the donors want to support the realization of the Foundation’s purpose with this donation. The Foundation is independent of Markku and Sirpa Jalkanen. Following receipt of the donation, the Foundation will be interested in 500,000 ordinary shares in the Company, representing approximately 0.45 per cent. of the total voting rights in the Company. In addition, on 3 June 2025, Markku and Sirpa Jalkanen have sold in aggregate 300,000 ordinary shares in the Company. Markku Jalkanen sold 200,000 ordinary shares and Sirpa Jalkanen sold 100,000 ordinary shares.

Further details are set out in the Notification of Dealing Form below.

Director/PCA	Holding prior to sale/disposal	Number of ordinary shares sold / disposed	Resultant interest in ordinary shares in the Company	Resultant percentage of voting rights in the Company
Markku Jalkanen	2,225,266	600,000	1,625,266	1.45%
Sirpa Jalkanen	1,188,168	200,000	988,168	0.88%

Following the above transactions, the aggregate holdings of Markku and Sirpa Jalkanen amount to 2,613,434 ordinary shares in the Company, representing approximately 2.33 per cent. of the voting rights in the Company.

For more information, please contact:

IR Partners, Finland (Media) Riina Tuominen Kare Laukkanen	+358 44 313 5005 riina.tuominen@irpartners.fi +358 50 553 9535 / +44 7 469 766 223 kare.laukkanen@irpartners.fi
FINN Partners, US (Media) Alyssa Paldo	+1 847 791-8085 alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP (Nominated Adviser and Broker) Sandy Jamieson, Jo Turner	+44 (0) 207 213 0880
Sisu Partners Oy (Certified Adviser on Nasdaq First North) Juha Karttunen Jukka Järvelä	+358 (0)40 555 4727 +358 (0)50 553 8990

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Markku Jalkanen Sirpa Jalkanen
2	Reason for notification
a.	Position/Status	Non-executive Director PCA
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Faron Pharmaceuticals Ltd.
b.	LEI	7437009H31TO1DC0EB42
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary Shares ISIN: FI4000153309
b.	Nature of the transaction	Disposal of ordinary shares
			Price(s) per share (p)	Volume(s)
			Nil €3.09816 Nil b) €3.0039	400,000 200,000 100,000 b) 100,000

d.	Aggregated information Volume Price	Transaction details (a) (1): Volume 36,773 Unit price: 3.18 EUR (2): Volume 63,227 Unit price: 3.20 EUR (3): Volume 32,006 Unit price: 3.09 EUR (4): Volume 27,875 Unit price: 2.95 EUR (5): Volume 26,594 Unit price: 2.98 EUR (6): Volume 5,000 Unit price: 3.07 EUR (7): Volume 8,525 Unit price: 2.89 EUR Transaction details (b) (1): Volume 32,006 Unit price: 3.09 EUR (2): Volume 27,875 Unit price: 2.95 EUR (3): Volume 26,594 Unit price: 2.98 EUR (4): Volume 5,000 Unit price: 3.06 EUR (5): Volume 8,525 Unit price: 2.89 EUR
e.	Date of the transaction	03/06/2025
f.	Place of the transaction	Nasdaq First North Growth Market

Faron Pharmaceuticals Ltd: Registration of New Shares

3.6.2025

Faron Pharmaceuticals Ltd | Company announcement | June 03, 2025 at 14:00:00 EEST

Registration of New Shares

Capitalised terms used in this announcement have the meanings given to them in the announcement made at 9.00 a.m. EEST 3 June 2025 regarding the amortisation payment and approval of share subscriptions based on special rights, unless the context provides otherwise.

Turku, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, has, as announced earlier today on 3 June 2025, approved the exercise of 352,989 Special Rights entitling to 352,989 new Shares, for an aggregate subscription price of EUR 907,499.42. Last week, on 27 May 2025, the Company announced that that the Board of Directors of Faron (the “Board”) had resolved to issue 5,000,000 treasury shares to the Company itself without consideration to prepare for any future conversions of the First Tranche Bond.

In total 5,352,989 new shares in the Company have today on 3 June 2025 been registered in the Finnish Trade Register. The shares rank pari passu in all respects with the existing shares of the Company. Following the issuance, the aggregate number of ordinary shares in the Company is 116,954,597. Shares held in treasury by the Company do not confer a right to dividends or other shareholder rights. Following the registration, the Company continues to have 5,000,000 shares in treasury and therefore, the total number of voting rights in Faron is 111,954,597 (the “Number of Shares and Votes”). This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the Number of Shares and Votes of the Company.

Trading in the new shares is expected to commence on First North and AIM on or around 4 June 2025.

For more information, please contact:

IR Partners, Finland (Media) Riina Tuominen Kare Laukkanen	+358 44 313 5005 riina.tuominen@irpartners.fi +358 50 553 9535 / +44 7 469 766 223 kare.laukkanen@irpartners.fi
FINN Partners, US (Media) Alyssa Paldo	+1 847 791-8085 alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP (Nominated Adviser and Broker) Sandy Jamieson, Jo Turner	+44 (0) 207 213 0880
Sisu Partners Oy (Certified Adviser on Nasdaq First North) Juha Karttunen Jukka Järvelä	+358 (0)40 555 4727 +358 (0)50 553 8990

About Faron Pharmaceuticals Ltd

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds

3.6.2025

Faron Pharmaceuticals Ltd | Company announcement | June 03, 2025 at 09:00:00 EEST

Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds

Turku, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the Company has approved the exercise of 352,989 special rights entitling to 352,989 new Shares, for an aggregate subscription price of EUR 907,499.42, in connection with the first scheduled amortisation payment of the First Tranche Bonds (as defined below), occurred on 2 June 2025.

The Company announced on 3 April 2025 that it had entered into a convertible bond arrangement for up to EUR 35 million with an entity managed by Heights Capital Management, Inc. (“HCM”) and resolved upon the issuance of amortising senior unsecured convertible bonds with an aggregated principal amount of EUR 15 million (the “First Tranche Bonds”) due 2 April 2028 to HCM, convertible into new and/or existing shares in the Company (the “Shares”). As previously announced, the Board of Directors of Faron has resolved to make amortisations and interest payments by converting the relevant amounts due into Shares (“Share Settlement Option”), unless it separately decides to make payments in cash. The exercise of the Company’s Share Settlement Option is effected by the bondholders exercising special rights entitling into Shares, as referred to in Chapter 10 of the Finnish Companies Act (“Special Rights”), issued in connection with the issuance of the First Tranche Bonds.

The Company has received a scheduled amortised payment notice from the bondholder for an aggregate amortised payment amount (including accrued interest) of EUR 907,500. As the Company has exercised its Share Settlement Option, the subscription price for the Shares subscribed for by the bondholder is EUR 2.5709 per Share, corresponding to 90 per cent of the lowest of (i) the volume weighted average price (“VWAP”) of a Share on the relevant payment date, and (ii) the lowest of the VWAPs of a Share on each of the five consecutive dealing days ending on (and including) the dealing day immediately preceding the relevant payment date. Therefore, the Company has approved the exercise of 352,989 Special Rights entitling to 352,989 new Shares, for an aggregate subscription price of EUR 907,499.42. The subscription price for the Shares subscribed for pursuant to the Special Rights is paid by setting off the Company’s debt to pay relevant amounts due under the First Tranche Bonds and recorded into the reserve for invested unrestricted equity.

The 352,989 Shares subscribed for and issued are expected to be registered in the Finnish Trade Register on or around 3 June 2025. The Shares will rank pari passu in all respects with the existing shares of the Company once they are registered with the Finnish Trade Register.

The Company will make applications for the admission of the newly issued Shares to trading on Nasdaq First North Growth Market Finland (“First North“) maintained by Nasdaq Helsinki Ltd (“Nasdaq Helsinki“) and on AIM (“AIM“), the market of that name operated by London Stock Exchange plc (the “LSE“) with said admissions expected to become effective and trading to commence on or around 4 June 2025 (the “Admissions”).

Following the issuance, the aggregate number of ordinary shares in the Company is 116,954,597. Shares held in treasury by the Company do not confer a right to dividends or other shareholder rights. Following the registration, the Company will continue to have 5,000,000 shares in treasury (issued by the Company to itself previously on 27 May 2025) and therefore, the total number of voting rights in Faron will be 111,954,597 (the “Number of Shares and Votes“). This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the Number of Shares and Votes of the Company.

For more information, please contact:

IR Partners, Finland (Media) Riina Tuominen Kare Laukkanen	+358 44 313 5005 riina.tuominen@irpartners.fi +358 50 553 9535 / +44 7 469 766 223 kare.laukkanen@irpartners.fi
FINN Partners, US (Media) Alyssa Paldo	+1 847 791-8085 alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP (Nominated Adviser and Broker) Sandy Jamieson, Jo Turner	+44 (0) 207 213 0880
Sisu Partners Oy (Certified Adviser on Nasdaq First North) Juha Karttunen Jukka Järvelä	+358 (0)40 555 4727 +358 (0)50 553 8990

About Faron Pharmaceuticals Ltd

Faron Pharmaceuticals Ltd: Issue of Treasury Shares to the Company

27.5.2025

Faron Pharmaceuticals Ltd | Company announcement | May 27, 2025 at 19:00:00 EEST

Issue of Treasury Shares to the Company

Turku, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the Board of Directors of Faron (the “Board”) has resolved to issue 5,000,000 treasury shares to the Company itself without consideration to further prepare for any future conversions of the First Tranche Bond (as defined below).

The Company previously announced on 3 April 2025 that it had entered into a convertible bond arrangement for up to EUR 35 million with an entity managed by Heights Capital Management, Inc. (“HCM”) and resolved upon the issuance of amortising senior unsecured convertible bonds with an aggregated principal amount of EUR 15 million (the “First Tranche Bonds”) due 2 April 2028 to HCM, convertible into new and/or existing shares in the Company (the “Shares”). The First Tranche Bonds generally amortise in equal instalments every two months and the Company has the option to redeem the bonds by issue of Shares (by way of the bondholders exercising special rights entitling to Shares, as referred to in Chapter 10 of the Finnish Companies Act) against such repayment instalment or by payment in cash during the term of the bonds. The first scheduled amortization is expected to occur on the 2 June 2025. A holder of the First Tranche Bonds may also decide to convert the outstanding principal amount of a First Tranche Bond or any instalment amount at any time during the term of the First Tranche Bonds at the initial Conversion Price (as defined in terms and conditions of the First Tranche Bonds, (“First Tranche Conditions”)) of EUR 2.93952 per Share.

In order to prepare especially for any advanced amortisation situations, and also for any future conversions of the First Tranche Bonds, the Board has today resolved to issue 5,000,000 treasury shares to the Company itself without consideration, in order to have registered shares readily available for conveyance to a bondholder. The Board may resolve upon all matters related to the treasury shares including, for example, their conveyance for other purposes than conversions of the First Tranche Bonds.

The 5,000,000 treasury shares issued to the Company itself are expected to be registered in the Finnish Trade Register on or around 3 June 2025. The treasury shares will rank pari passu in all respects with the existing shares of the Company once they are registered with the Finnish Trade Register and further conveyed from treasury.

The Company will make applications for the admission of the newly issued treasury shares to trading on shares on Nasdaq First North Growth Market Finland (“First North“) maintained by Nasdaq Helsinki Ltd (“Nasdaq Helsinki“) and on AIM (“AIM“), the market of that name operated by London Stock Exchange plc (the “LSE“) with said admissions expected to become effective and trading to commence on or around 4 June 2025 (the “Admissions”).

Following the issuance, the aggregate number of ordinary shares in the Company is 116,601,608. As long as the shares are held in treasury by the Company, they do not confer a right to dividends or other shareholder rights. Following the registration, the Company will have 5,000,000 shares in treasury and therefore, the total number of voting rights in Faron will continue to be 111,601,608 (the “Number of Shares and Votes“) until further announced. This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the Number of Shares and Votes of the Company.

For more information, please contact:

IR Partners, Finland (Media) Riina Tuominen Kare Laukkanen	+358 44 313 5005 riina.tuominen@irpartners.fi +358 50 553 9535 / +44 7 469 766 223 kare.laukkanen@irpartners.fi
FINN Partners, US (Media) Alyssa Paldo	+1 847 791-8085 alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP (Nominated Adviser and Broker) Sandy Jamieson, Jo Turner	+44 (0) 207 213 0880
Sisu Partners Oy (Certified Adviser on Nasdaq First North) Juha Karttunen Jukka Järvelä	+358 (0)40 555 4727 +358 (0)50 553 8990

About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.